6-K, 6-K/A, 8-K, 8-K/A, 10-C
Filing Types
Advaxis, Inc.
Companies

206 filings

Newest first
8-K
ADXS Advaxis, Inc.
16 Jan 20
Other Events
8-K
ADXS Advaxis, Inc.
7 Jan 20
Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer
8-K
ADXS Advaxis, Inc.
20 Dec 19
Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update
8-K
ADXS Advaxis, Inc.
25 Oct 19
Advaxis Announces Business and Pipeline Update
8-K
ADXS Advaxis, Inc.
4 Oct 19
Other Events
8-K
ADXS Advaxis, Inc.
13 Sep 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8-K
ADXS Advaxis, Inc.
9 Sep 19
Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update
8-K
ADXS Advaxis, Inc.
6 Sep 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8-K
ADXS Advaxis, Inc.
22 Aug 19
Advaxis, Inc. Issues Letter to Shareholders
8-K
ADXS Advaxis, Inc.
31 Jul 19
Material Modifications to Rights of Security Holders
8-K
ADXS Advaxis, Inc.
25 Jul 19
Advaxis, Inc. Announces Pricing of $16 Million Public Offering
8-K
ADXS Advaxis, Inc.
15 Jul 19
Other Events
8-K
ADXS Advaxis, Inc.
27 Jun 19
Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of its Phase 3 AIM2CERV Study
8-K
ADXS Advaxis, Inc.
10 Jun 19
Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update
8-K
ADXS Advaxis, Inc.
15 May 19
Other Events
8-K
ADXS Advaxis, Inc.
13 May 19
Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer
8-K
ADXS Advaxis, Inc.
15 Apr 19
Other Events
8-K
ADXS Advaxis, Inc.
5 Apr 19
Entry into a Material Definitive Agreement
8-K
ADXS Advaxis, Inc.
29 Mar 19
Material Modifications to Rights of Security Holders
8-K
ADXS Advaxis, Inc.
15 Mar 19
Material Modifications to Rights of Security Holders